Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002933166 | SCV003265393 | uncertain significance | Jeune thoracic dystrophy | 2022-03-12 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with leucine, which is neutral and non-polar, at codon 198 of the IFT80 protein (p.Ser198Leu). This variant is present in population databases (rs370411287, gnomAD 0.004%). This variant has not been reported in the literature in individuals affected with IFT80-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004067063 | SCV004885162 | uncertain significance | Inborn genetic diseases | 2023-10-03 | criteria provided, single submitter | clinical testing | The c.593C>T (p.S198L) alteration is located in exon 7 (coding exon 6) of the IFT80 gene. This alteration results from a C to T substitution at nucleotide position 593, causing the serine (S) at amino acid position 198 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005028028 | SCV005657919 | uncertain significance | Asphyxiating thoracic dystrophy 2 | 2024-03-07 | criteria provided, single submitter | clinical testing |